FASEB J.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
fj.07-8873comv1
22/2/530    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kajiya, K.
Right arrow Articles by Detmar, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kajiya, K.
Right arrow Articles by Detmar, M.
Published online before print September 13, 2007 as doi: 10.1096/fj.07-8873com.

Nitric oxide mediates lymphatic vessel activation via soluble guanylate cyclase {alpha}1{beta}1-impact on inflammation

Kentaro Kajiya, Reto Huggenberger, Ines Drinnenberg, Beijia Ma, and Michael Detmar

E-mail contact: michael.detmar@pharma.ethz.ch

The lymphatic vascular system regulates tissue fluid homeostasis and the afferent phase of the immune response, and it is also involved in tumor metastasis. There is increasing evidence that lymphatic vessels also mediate acute and chronic inflammation. However, the mechanisms and functional consequences of lymphangiogenesis under inflammatory conditions are largely unknown. Here, we show that lymphatic endothelial cells (LECs) specifically express the {alpha}1{beta}1 isoform of soluble guanylate cyclase (sGC), that vascular endothelial growth factor-A potently induces sGC{alpha}1{beta}1, and that nitric oxide (NO) -induced LEC proliferation, migration, and cGMP production in LECs are specifically dependent on sGC{alpha}1{beta}1. Moreover, the specific sGC inhibitor NS-2028 completely prevents ultraviolet B-irradiation-induced lymphatic vessel enlargement, edema formation, and skin inflammation in vivo. These findings identify a crucial role of the NO/sGC{alpha}1{beta}1/cGMP pathway in modulating lymphatic vessel function. The blockade of sGC{alpha}1{beta}1 signaling might serve as a novel therapeutic strategy for inhibiting lymphangiogenesis and inflammation, in addition to its effects on the blood vasculature.—Kajiya, K., Huggenberger, R., Drinnenberg, I., Ma, B., and Detmar, M. Nitric oxide mediates lymphatic vessel activation via soluble guanylate cyclase {alpha}1{beta}1-impact on inflammation.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by The Federation of American Societies for Experimental Biology.